Figure S7 from Treatment of prostate cancer with CD46 targeted ²²⁵Ac alpha particle radioimmunotherapy

Anil P. Bidkar; Sinan Wang; Kondapa Naidu Bobba; Emily Chan; Scott Bidlingmaier; Emily A. Egusa; Robin Peter; Umama Ali; Niranjan Meher; Anju Wadhwa; Suchi Dhrona; Chandrashekhar Dasari; Denis Beckford-Vera; Yang Su; Ryan Tang; Li Zhang; Jiang He; David M. Wilson; Rahul Aggarwal; Henry F. VanBrocklin; Youngho Seo; Jonathan Chou; Bin Liu; Robert R. Flavell

doi:10.1158/1078-0432.27030388.v1

Abstract

Figure S7: Analysis of CD46 expression in correlation with of the [225Ac]DOTA-YS5 uptake and DNA damage. Digital autographs, H &E staining, and immunofluorescence (Rabbit Isotype control+DAPI, CD46 & phospho-γ-H2Ax) of the tumor tissues injected with [225Ac]DOTA-YS5 for day 1, day 2, day 4, and day 7.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bidkar et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522e11 https://doi.org/10.1158/1078-0432.27030388.v1

View at Publisher

Ask AI

Bookmark

Share

Figure S7 from Treatment of prostate cancer with CD46 targeted ²²⁵Ac alpha particle radioimmunotherapy

Abstract

Discussion

Cite This Study

Figure S7 from Treatment of prostate cancer with CD46 targeted ²²⁵Ac alpha particle radioimmunotherapy

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers